Scientists from the University College London made a new discovery regarding the HIV virus.
The researchers learned the common HIV therapy tenofovir was less effective against certain strains of the pathogen after studying an estimated 2,000 patients, writes the BBC. Tenofovir is typically used in combination with other medication to suppress the growth of this infection.
A comparison was done between HIV patients in Africa versus those in Europe. Individuals in Africa were 60 percent more resistant to tenofovir whereas European patients experienced 20 percent more resistance.
Irregular dosing of the drug was partly to blame as well as sub-standard administration of the medication.
Lead author Dr. Ravi Gupta told the BBC, “If the right levels of the drug are not taken, as in they are too low or not regularly maintained, the virus can overcome the drug and become resistant.”
Gupta added that there should be a simultaneous global initiative and cash investment to improve facilities and disease monitoring in African countries.
The research was published Thursday in The Lancet Infectious Disease journal.
Filed Under: Drug Discovery
